UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001727
Receipt number R000002081
Scientific Title Japanese multicenter study of short- and long-term efficacy and safety of itraconazole in the treatment of chronic necrotizing pulmonary aspergillosis
Date of disclosure of the study information 2009/02/23
Last modified on 2011/04/21 17:44:51

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Japanese multicenter study of short- and long-term efficacy and safety of itraconazole in the treatment of chronic necrotizing pulmonary aspergillosis

Acronym

Japanese multicenter study of itraconazole for chronic necrotizing pulmonary aspergillosis

Scientific Title

Japanese multicenter study of short- and long-term efficacy and safety of itraconazole in the treatment of chronic necrotizing pulmonary aspergillosis

Scientific Title:Acronym

Japanese multicenter study of itraconazole for chronic necrotizing pulmonary aspergillosis

Region

Japan


Condition

Condition

Chronic Necrotizing Pulmonary Aspergillosis

Classification by specialty

Medicine in general Pneumology Infectious disease

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

1) To verify short- and long-term efficacy and safety of itraconazole in the treatment of chronic necrotizing pulmonary aspergillosis
2) To measure the MIC of itraconazole against Aspergillus, and perform PK/PD analyses

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Clinical success rate

Key secondary outcomes

1) Safety
2) Isolation frequency (%) of each Aspergillus species through culture
3) MICs of antifungal agents against isolated Aspergillus strains
4) Correlation between MIC and clinical efficacy
5) Measurement of plasma concentration of itraconazole


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Itraconazole

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Inclusion starts with admission to hospital regardless of whether an inpatient or outpatient
2) Meeting diagnostic criteria for clinical diagnosis or definitive diagnosis for respiratory medicinal CNPA described in "2007 Guideline for the diagnosis and treatment of profound mycosis"
3) Able to be followed up for at least 12 weeks
4) If pretreated with an antifungal agent, its use must have been continued for at least 1 month, with no tendency toward clinical improvement (antifungal agents are not specified)
5) Written informed consent obtained

Key exclusion criteria

1) Pregnant or potentially pregnant women, or lactating women
2) Patients with any underlying diseases considered to have a significant impact on the course of treatment in this clinical study such as progressive cancer, serious heart failure, or serious respiratory failure
3) Patients with a stable lesion restricted to one area of the lung and considered a candidate for surgical resection
4) Patients receiving drugs contraindicated with itraconazole
5) Patients with history of hypersensitivity to itraconazole
6) Presence or history of serious liver disease
7) Patients with severe renal impairment (creatinine clearance < 30 mL/min)
8) Patients for whom inclusion in this clinical study is considered potentially disadvantageous
9) Patients who had been previously included in this study

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoshihito Niki

Organization

School of Medicine, Showa University

Division name

Clinical infectious Diseases

Zip code


Address

1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Koichiro Yoshida

Organization

School of Medicine, Showa University

Division name

Clinical infectious Diseases

Zip code


Address

1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555

TEL


Homepage URL


Email



Sponsor or person

Institute

Department of Clinical infectious Diseases, School of Medicine, Showa University

Institute

Department

Personal name



Funding Source

Organization

Japan Association of Health Service

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2009 Year 02 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2008 Year 04 Month 14 Day

Date of IRB


Anticipated trial start date

2008 Year 06 Month 01 Day

Last follow-up date

2011 Year 03 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2009 Year 02 Month 23 Day

Last modified on

2011 Year 04 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002081


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name